Advanced Filters
noise

neoplasms Clinical Trials

A listing of neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 14,299 clinical trials
N Neelam Lal

Axitinib + Ipilimumab in Advanced Melanoma

The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.

18 years of age All Phase 2
C Carol Ann Wiggs, BSN

A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy

The purpose of this study is to determine the safety and feasibility of administering the Tetanus Diptheria Vaccine (Td) or Polio Boost Immunization (IPOL) to patients with metastatic melanoma who are receiving immune checkpoint inhibitor (IO) therapy per standard of care. Subjects will have the vaccine at cycle 4 of …

18 years of age All Phase 1
A Ann Lau Clark, RN, MSN

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.

18 - 89 years of age All Phase 1
S Seitz Barbara, PhD

Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors

Checkpoint inhibitor such as anti-CTLA-4 and anti-PD-1 are known to block inhibitory signals and increase the immune antimutoral response. Nivolumab and Ipilimumab association is considered as a more efficient immunotherapy to treat advanced melanoma. This combined immunotherapy is also responsible of severe immunes toxicyties. Identification of predictives biomarqueurs remains a …

18 years of age All Phase N/A
B Bridney Stewart

Excision of Lymph Node Trial (EXCILYNT) (Mel69)

The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same area of the lymph node excision. The study team is also trying to find out the side …

18 years of age All Phase N/A
D Devarati Mitra

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Prior studies of patients with more advanced melanoma have shown nodal …

18 years of age All Phase 2
C Carol Ann Wiggs, BSN

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

This phase 1/2 trial will be conducted in two parts. Part 1 (Dose Selection) is designed to find the dose of dapansutrile with acceptable tolerability in combination with pembrolizumab. Part 1 will consist of up to 2 dose selection cohorts to evaluate the safety and tolerability of dapansutrile + pembrolizumab …

18 years of age All Phase 1/2

Immune Profiles Evolution Under Immunotherapy for Melanoma

The primary objective of the study aims to compare the immune profiles (circulating cytokines and lymphocytes) before and after (6 to 8 weeks) the first infusion of immune checkpoint inhibitors in patients with melanoma treated in the adjuvant setting(cohort A) or in metastatic setting(cohort B); and to study the association …

18 years of age All Phase N/A
M Michiel MC

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response

Patients with advanced melanoma are, amongst others, currently treated with nivolumab monotherapy or with nivolumab and ipilimumab followed by nivolumab. Even though registration studies administered nivolumab in a 3 mg/kg 2 weekly scheme, currently, nivolumab monotherapy is either administered in a 240 mg 2-weekly scheme or in a 6 mg/kg …

18 years of age All Phase 4
J Jun Guo, Director

OH2 Injection in Combination With HX008 for Melanoma.

This phase Ib study evaluates the safety and efficacy of OH2 in combination with HX008, an anti-PD-1 antibody, in patients with Melanoma. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the …

18 - 75 years of age All Phase 1/2

Simplify language using AI